1312008-67-5 Usage
Uses
Used in Pharmaceutical Industry:
6-chloro-1H-Indazole-5-carbonitrile is used as a building block for the development of potential drug candidates, particularly for the treatment of various diseases. Its unique chemical structure allows for the creation of new and effective pharmaceutical compounds.
Used in Agrochemical Industry:
6-chloro-1H-Indazole-5-carbonitrile is used as an intermediate in the synthesis of agrochemicals, contributing to the development of new and improved products for agricultural applications.
Used in Organic Materials Industry:
6-chloro-1H-Indazole-5-carbonitrile is used as a precursor in the production of various fine chemicals and organic materials, playing a crucial role in the synthesis of a wide range of compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1312008-67-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,0,0 and 8 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1312008-67:
(9*1)+(8*3)+(7*1)+(6*2)+(5*0)+(4*0)+(3*8)+(2*6)+(1*7)=95
95 % 10 = 5
So 1312008-67-5 is a valid CAS Registry Number.
1312008-67-5Relevant academic research and scientific papers
OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
-
Page/Page column 25, (2012/11/13)
Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
-
Page/Page column 17; 45-46, (2011/07/07)
Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.
